Olivier Micheau PhD, Molecular and Cellular Biology : Expertise in TNF Signaling
Course and current status
Research :
- Since 2024 Heading the DesCarTes Team CTM INSERM 1231
- Since 2022 Ranked in the top list of Biology & Biochemistry scientists at Research.com.
- Since February 2022 : Specialty Chief Editor Frontiers Cell Death : Apoptosis
- Since 2019 :SBBIO1 expert panel member FWO (Flanders Research Foundation)
- 2018-2022 : Scientific advisor Axis III Health, I-SITE
- Since 2015: Research director (DR2, INSERM), INSERM U866, UFR Science de Santé, 7 Bd Jeanne d’Arc; F21000 Dijon, France.
- 2015-2018 : Member of the Fondation ARC scientific council CN4
- 2012-2016 : Member of the INSERM scientific council CSS3
- 2012-2020 : Associate Editor British Journal of Pharmacology
- 2003-2014 : Chargé de Recherche (Ass. Professor), INSERM U866 (former U517), Faculty of Medicine, 7 Bd Jeanne d’Arc; F21000 Dijon, France.
- 2008- 2012 INSERM Interface contract with Hospitals (Translational research with the CGFL cancer center).
- 1999-2003: Post-doctoral Research Scientist, Institute of Biochemistry, Lausanne, Switzerland in Jürg Tschopp’s laboratory.
- 1995-1999: PhD in Molecular And Cellular Biology, INSERM U517, University of Burgundy, Dijon, France – Supervised by: Dr Marie Thérèse Dimanche-Boitrel.
Education :
- 2005: Habilitation à diriger des recherches (HDR, required to supervise PhDs), University of Burgundy, Dijon, France.
- 1994-1995: DEA (Master 2nd year) INSERM U517, Dijon University of Burgundy, Dijon, France.
- 1992-1993: Maîtrise de Biologie Cellulaire : Génétique (1st Year of Master Cellular biology and genetics), Paul Sabatier University, Toulouse, France.
- 1991-1992: Bsc (Bachelor of Science) Biochemistry, University of Central Lancashire, Preston, UK.
Selected International funding :
- 2023- : Horizon MSCA-SE-2022 CHIRON
- 2017-2022 : Horizon H2020 RISE (Research & Innovation Staff Exchange) DISCOVER (EU#777995)
- 2017-2021 : CAPES-COFECUB Me 888/17- Brazil
- 2007-2010 : FP7 RTN ApoTrain
Scientific summary
My research interests, centered on TNF receptor members, have led to several important discoveries, including cross-talks between TNF receptors such as Fas and conventional chemotherapeutic drugs (Micheau et al. 1997and 1999) or elucidation of the molecular mechanisms underlying TNFR1 pleiotropic signaling (Micheau et al, 2001 and 2003)
My actual interest is to further understand TRAIL signal transduction in order to optimize TRAIL-based antitumor therapeutic strategies (Mérino et al. 2006; Morizot et al. 2011; Jacquemin et al. 2012; Zakaria et al. 2015; Dufoura et al. 2017;Dufourb et al. 2017; Dubuisson et al. 2019; Belkhala et al. 2019).
Selected publications
Micheau, O., and Tschopp, J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. 2003 Cell 114, 181-190.
Mérino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., and Micheau, O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. 2016 Mol Cell Biol 26, 7046-7055.
Morizot, A., Merino, D., Lalaoui, N., Jacquemin, G., Granci, V., Iessi, E., Lanneau, D., Bouyer, F., Solary, E., Chauffert, B., Saas, P., Garrido, C., Micheau, O. Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. 2011 Cell Death Differ. 18, 700-711.
Zakaria AB, Picaud F, Rattier T, Pudlo M, Saviot L, Chassagnon R, Lherminier J, Gharbi T, Herlem G* and Micheau O*. Nanovectorization of TRAIL with single wall carbon nanotubes enhances tumor cell killing. 2015 Nano Letters 15(2):891-895.
Dufour F, Rattier T, Constantinescu AA, Zischler L, Morlé A, Ben Mabrouk H, Humblin E, Jacquemin G, Szegezdi E, Delacote F, Marrakchi N, Guichard G, Pellat-Deceunynck C, Vacher P, Legembre P, Garrido C, and Micheau O. TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress. 2017 Oncotarget 8(6):9974-9985.
Dufour F*, Rattier T*, Shirley S*, Picarda G, Constantinescu AA, Morlé A, Zakaria AB, Marcion G, Causse S, Szegezdi E, Zajonc DM, Seigneuric R, Guichard G, Gharbi T, Picaud F, Herlem G, Garrido C, Schneider P, Benedict CA and Micheau O. N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death. 2017 Cell Death Differ. 24(3), 500-510.
Belkahla, H., Mazario, E., Sangnier, A. P., Lomas, J. S., Gharbi, T., Ammar, S., Micheau*, O., Wilhelm*, C., and Hemadi*, M. TRAIL acts synergistically with iron oxide nanocluster-mediated magneto- and photothermia. 2019 Theranostics 9, 5924-5936. (*equal contribution)
Dubuisson, A., Favreau, C., Fourmaux, E., Lareure, S., Rodrigues-Saraiva, R., Pellat-Deceunynck, C., El Alaoui, S., and Micheau, O. Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization. 2019 Cell death & disease 10, 101.
Belkahla H, Constantinescu AA, Gharbi T, Barbault F, Chevillot-Biraud A, Decorse P, Micheau O, Hemadi M*, Ammar S* Grafting TRAIL through either Amino or Carboxylic Groups onto Maghemite Nanoparticles: Influence on Pro-Apoptotic Efficiency 2021 Nanomaterials 11(2), 502.
Cardoso Alves L, Corazza N, Micheau O, Krebs P. The multifaceted role of TRAIL signaling in cancer and immunity. 2020 FEBS J 288(19):5530-5554.
Micheau O, Rizzi M, Smulski C. Editorial: TNFR Superfamily Oligomerization and Signaling. 2021 Front. Cell Dev. Biol. 9:682472
Radoua A, Pernon B, Pernet N, Jean C, Elmallah M, Guerrache A, Constantinescu AA, Hadj Hamou S, Devy J, Micheau O. ptARgenOM - a flexible vector for CRISPR/CAS9 non-viral delivery Small Methods 2023, 2300069.
Groeneveld C, Sanchez-Quiles V, Dufour F, Shi M, Dingli F, Gentric G, Nicolle R, Chapeaublanc E, Poullet P, Vacherot F, Benhamou S, Lebret T, Micheau O, Mechta-Grigoriou F, Zinovyev A, Loew D, Allory Y, de Reyniès A, Bernard-Pierrot I, Radvanyi F. Proteogenomic characterization of bladder cancer reveals sensitivity to TRAIL-induced apoptosis in FGFR3-mutated tumors. European Urology, 2023.
